Amedisys Reports First Quarter 2018 Financial Results and Reaffirms 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amedisys (AMED) Tops Q1 EPS by 12c, Offers FY Guidance
May 7, 2018 5:01 PM EDTAmedisys (NASDAQ: AMED) reported Q1 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $399.3 million versus the consensus estimate of $395.28 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $2.97-$3.08, versus the consensus of $3.00. Amedisys sees... More
